Unlike other types of kidney cancer, RMC poses a significant challenge with less than 5 percent of patients surviving beyond three years using standard treatments. However, recent research offers new hope.

Renal medullary carcinoma may not be on the radar of all primary care providers. Watch as expert Dr. Kimryn Rathmell provides advice on questions those with sickle cell trait can ask their doctors.

• The molecular profile of RMC distinguishes it from other renal malignancies

• RMC harbors a high number of focal chromosomal alterations

• RMC has a distinct immune profile characterized by upregulation of cGAS-STING

• DNA replication stress is a hallmark of RMC that can be therapeutically targeted